These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. High resolution MRI of MCF7 human breast tumors: complemented use of iron oxide microspheres and Gd-DTPA. Furman-Haran E; Margalit R; Grobgeld D; Degani H J Magn Reson Imaging; 1998; 8(3):634-41. PubMed ID: 9626879 [TBL] [Abstract][Full Text] [Related]
8. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. Turetschek K; Roberts TP; Floyd E; Preda A; Novikov V; Shames DM; Carter WO; Brasch RC J Magn Reson Imaging; 2001 Jun; 13(6):882-8. PubMed ID: 11382948 [TBL] [Abstract][Full Text] [Related]
9. Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors. Turetschek K; Huber S; Helbich T; Floyd E; Tarlo KS; Roberts TP; Shames DM; Wendland MF; Brasch RC Acad Radiol; 2002 May; 9 Suppl 1():S112-4. PubMed ID: 12019843 [No Abstract] [Full Text] [Related]
14. The potential value of iron oxide nanoparticles in brain tumor treatment. Gutin PH AJNR Am J Neuroradiol; 2002 Apr; 23(4):505. PubMed ID: 11950633 [No Abstract] [Full Text] [Related]
15. Quantitative assessment of the contrast behavior of typical focal hepatic lesions before and after the administration of Gd-DTPA and superparamagnetic iron oxide particles. Helmberger T; Holzknecht N; Reiser M Acad Radiol; 2002 Aug; 9 Suppl 2():S468-72. PubMed ID: 12188311 [No Abstract] [Full Text] [Related]
16. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Preda A; van Vliet M; Krestin GP; Brasch RC; van Dijke CF Invest Radiol; 2006 Mar; 41(3):325-31. PubMed ID: 16481916 [TBL] [Abstract][Full Text] [Related]
17. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908 [TBL] [Abstract][Full Text] [Related]
18. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. Clément O; Pradel C; Siauve N; Frouin F; Bruneteau G; Kahn E; Frija G; Cuénod CA Acad Radiol; 2002 Aug; 9 Suppl 2():S328-9. PubMed ID: 12188264 [No Abstract] [Full Text] [Related]
19. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis. Kato N; Takahashi M; Ihara S; Tsujimoto T; Miyazawa T Acad Radiol; 1998 Apr; 5 Suppl 1():S83-5. PubMed ID: 9561051 [No Abstract] [Full Text] [Related]
20. Use of intravascular contrast agents in MRI. Bjørnerud A; Wendland MF; Johansson L; Ahlstrom HK; Higgins CB; Oksendal A Acad Radiol; 1998 Apr; 5 Suppl 1():S223-5. PubMed ID: 9561086 [No Abstract] [Full Text] [Related] [Next] [New Search]